Bloomberg Businessweek Publishes Long-Form Feature 'Peptides Fuel a Multibillion-Dollar Startup Race' Framing the Post-PCAC-Vote Investor Landscape as a Legalization Gold Rush and Profiles the Compounding-Pharmacy, Telehealth, Manufacturing, and Startup Ecosystem Positioning to Capture the Estimated $10-19 Billion Non-GLP-1 Peptide Market Analyst Jonah Lupton Projected for Hims & Hers by 2030 if the Company Captures 4-5% of Combined GLP-1 and Non-GLP-1 Peptide Markets Following the July 23-24 PCAC 6-of-7 Recommendation
Bloomberg Businessweek published a long-form feature this week titled 'Peptides Fuel a Multibillion-Dollar Startup Race' covering the peptide industry's post-PCAC-vote investor landscape. The story frames the July 23-24 PCAC recommendation of 6 of 7 peptides for the Section 503A Bulks List as the trigger for a legalization gold rush and profiles the compounding-pharmacy, telehealth, manufacturing, and startup ecosystem positioning to capture what analysts describe as the multibillion-dollar non-GLP-1 peptide market. The feature draws on the analyst framing established earlier in 2026 (Jonah Lupton's projection that Hims & Hers could generate $10-19 billion in annual peptide-related revenue by 2030 if the company captures 4-5% of combined GLP-1 and non-GLP-1 peptide markets) and profiles the venture-capital financing wave, including the General Bio $7.4 million seed round for oral peptide platform work (Axios Pro exclusive July 20), the MindRank $52 million Series B for AI-driven peptide discovery (July 10 digest coverage), and the Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide (July 19-20 digest coverage). The Bloomberg piece anchors the investment thesis on the 6-of-7 PCAC recommendation while noting that FDA rulemaking to actually add BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon to the 503A list takes 6-18 months per substance from the date the agency decides to act.